Oct 31, 2024 6:30am EDT Matinas BioPharma Announces the Termination of MAT2203 Partnership Negotiations and Implements Immediate Workforce Reduction
Aug 14, 2024 4:05pm EDT Matinas BioPharma Reports Second Quarter 2024 Financial Results and Provides a Business Update
Aug 07, 2024 7:00am EDT Matinas BioPharma to Webcast Conference Call to Discuss Second Quarter 2024 Financial Results and Provide a Business Update on August 14, 2024
Jun 24, 2024 8:30am EDT Matinas BioPharma Reports Successful Treatment of Patient with Limb-Threatening Mucor Infection in its Oral MAT2203 Compassionate/Expanded Use Access Program
Jun 13, 2024 7:00am EDT Matinas BioPharma’s Oral MAT2203 to Be Featured in Fireside Chat Hosted by A.G.P. with Antifungal Expert Dr. David S. Perlin
May 16, 2024 7:00am EDT New In Vitro Data Showing Matinas BioPharma’s LNC Platform Delivering Small Oligonucleotides Presented at TIDES USA 2024
May 09, 2024 4:05pm EDT Matinas BioPharma Reports First Quarter 2024 Financial Results and Provides a Business Update
May 07, 2024 8:00am EDT Matinas BioPharma’s LNC Platform for the Delivery of Small Oligonucleotides Featured in Two Presentations at the ASGCT Annual Meeting
May 02, 2024 7:00am EDT Matinas BioPharma to Webcast Conference Call to Discuss First Quarter 2024 Financial Results and Provide a Business Update on May 9, 2024
Apr 30, 2024 8:00am EDT In Vivo Efficacy of Matinas BioPharma’s Oral MAT2203 in Pulmonary Mucormycosis Published in Journal of Antimicrobial Agents and Chemotherapy
